Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomics-Based Target Therapy for Pediatric Relapsed/Refractory Malignancy
NCT02638428Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2015
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib, crizotinib, dasatinib, erlotinib, everolimus in solid tumor, acute myeloid leukemia (AML), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
axitinibcrizotinibdasatiniberlotinibeverolimus
03
Conditions
solid tumoracute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02638428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638428.